• Lori Buswell, ANP-BC, OCN

     
    Lori Buswell, ANP-BC, OCN
     
    Vice President, Nursing and Clinical Services, Satellite and Network Affiliates

    Phone: 617-632-2526
    Email: lori_buswell@dfci.harvard.edu

     
     

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

    Biography

    I am currently a VP in Nursing and Clinical Services overseeing DFCI’s satellite centers and network affiliates. I also oversee staff who support clinical and revenue cycle systems for the DFCI enterprise such as scheduling systems, electronic medical records and order entry systems. I have recently become involved in global health and am a member of the DFCI Center for Global Cancer Medicine. In that role, I work closely with Partners in Health and help to develop, support and build in country capacity for oncology programs in Haiti and Rwanda.

    Background

    Education and Training
    University of New Hampshire, MS, 1999
    University of Massachusetts at Boston, BS, 1989
    Peter Bent Brigham School of Nursing, 1983

    Certification
    Oncology Certified Nurse (OCN)

    Awards

    • President's Award for Nursing Execllence, Dana-Farber Cancer Institute, 2012
    • Thomas Kloss Leadership Development Award, Dana-Farber Cancer Institute, 2000
    • Best of the Online Journal Award, Sigma Theta Tau, 1999
    • Oncology Nursing Certification Corporation Masters Scholarship, 1997
    • Peter Bent Brigham School of Nursing Alumni Association Award, 1983

    Select Publications

    • Coleman, C.N., Noll, L., Riese, N., Buswell, L., Howes, A.E., Loeffler, J.S., Alexander, E. III, Wen, P., Harris, J.R., Kramer, R.A., Hurwitz, S.J., Neben, T.Y., Grisby, P. Final report of the phase I trial of continuous infusion etanidazole (SR2508): A Radiation Oncology Therapy Group study. Int J Radiat Oncol Biol Phys. 22: 577-580, 1992.
    • Coleman, C.N., Buswell, L., Noll, L., Riese, N., Rose, M.A. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 22:565-568, 1992.
    • Coleman, C.N., Riese, N., Buswell, L., et al, Clinical trials of etanidazole (SR2508): RTOG and Joint Center for Radiation Therapy trials. In Radiation Research, A Twentieth-Century Perspective. WC Dewey, et al (eds). Academic Press, San Diego, 1992, p. 595-600.
    • Hurwitz, S.J., Coleman, C.N., Riese, N., Loeffler, J.S., Alexander, E. III, Buswell, L., Neben, T.Y., Shargel, L., Kramer, R.A. Distribution of etanidazole into human brain tumors: Implications for treating high grade gliomas. Int J Radiat Oncol Biol Phys. 22:573-576, 1992.
    • Buswell, L., Recht, A., Clark, J., Ravikumar, T., Busse, P.M., Coleman, C.N. Combined-modality therapy of esophagus cancer with radiotherapy, etanidazole and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicity and outcome. Int J Radiat Oncol Biol Phys. 29:535-540, 1994.
    • Beard, C., Buswell, L., Rose, M.A., Noll, L., Johnson, D., Coleman, C. N. Phase II trial of external beam radiation with etanidazole (SR2508) for the treatment of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 29:611-616, 1994.
    • Halberg F.E., Cosmatis, D., Gunderson, L.L., Noyes, R.D., Hanks, G.R., Buswell, L., Nagorney, D.M., Coleman, C.N. RTOG #89-06: a phase I pilot study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies. Int Radiat Oncol Biol Phys. 28: 201-206, 1994.
    • Riese, N.E., Rieker, P., Wen, P., Buswell, L. A pilot study: Quality of life in primary brain tumor patients. Quality of Life Newsletter, 9: 10, 1994.
    • Shulman, L.N., Buswell, L., Goodman, H., Muto, M., Berkowitz, R, Teicher, B., Kusumoto, T., Hurwitz, S.J., Kalish, L.A., Coleman, C.N. Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer. Int J Radiat Oncol Biol Phys. 29: 545-548, 1994.
    • Shulman, L.N., Buswell, L., Kalish, L.A., Coleman, C.N. Use of the hypoxic cell sensitizer etanidazole (SR2508) with intravenous melphalan and predinsone in the treatment of multiple myeloma: a pharmacokinetic study. Int J Radiat Oncol Biol Phys. 29: 541-543, 1994.
    • Watkins-Brunner, D., Scott, C., Lawton, C., Delrowe, J., Rotman, M., Buswell, L., Beard, C., Cella, D. RTOG’s first quality of life study-RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 33: 901-906, 1995.
    • Bornstein, B.A., Herman, T.S., Hansen, J.L., Buswell, L., Zouranjian, P.S., Fraser, S.M., Teicher, B.A., Svenson, G.K., Coleman, C.N. Pilot Study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours. Int J Hyperthermia. 11: 489-499, 1995.
    • Buswell, L. and Kunsman, J. Computers link clinical trials registration and patient information. Oncol Nurs Forum. 24: 1500, 1997.
    • Riese, N.E., Buswell, L., Noll, L., Pajak, T.F., Stetz, J., Lee, D.J., Coleman, C.N. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. Int J Radiat Oncol Biol Phys. 39: 855-858, 1997.
    • Bunnell, C. A., Thompson, L., Buswell, L., Berkowitz, R., Muto, M., Sheets, E., Shulman, L. N. A phae I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer. 82: 561-566, 1998.
    • Buswell, L. and Beyea, Suzanne. Flushing protocols for tunneled central venous catheters: an integrative review of the literature. The Online Journal of Knowledge Synthesis for Nursing. 5: Document no. 3, 1998.
    • Beard, C.J., Lamb, C., Buswell, L., Schneider, L., Propert, K.J., Gladstone, D., D’Amico, A., Kaplan, I. Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 41: 257-262, 1998.
    • Shulman, L.N., Buswell, L., Riese, N., Doherty, N., Loeffler, J.S., von Roemling, R., Coleman, C. N. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys. 44:349-53, 1999.
    • Cross, C.K., Berman, S., Buswell, L., Johnson, B, Baldini, E. E. Prospective hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 58:1098-105, 2004.
    • Buswell, L.A., Reid Ponte, P., Shulman, L.N., Provider Practice Models in Ambulatory Incology Practice: Analysis of Productivity, Revenue and Priovider and Pateint Satisfaction. Journal of Oncology Practice.5:188192, 2010.
    • Book Review: Buswell, L., and Reid Ponte, P.(2011). Book Review: Using Electronic Health Records to Transform Care Delivery. Journal of Nursing Administration. 41(4); 159-161.